Cytek Biosciences Inc (CTKB)vsEdwards Lifesciences Corp (EW)
CTKB
Cytek Biosciences Inc
$4.63
-1.70%
HEALTHCARE · Cap: $575.90M
EW
Edwards Lifesciences Corp
$82.67
+1.20%
HEALTHCARE · Cap: $48.01B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 2911% more annual revenue ($6.07B vs $201.49M). EW leads profitability with a 17.7% profit margin vs -33.0%. EW earns a higher WallStSmart Score of 55/100 (C).
CTKB
Hold41
out of 100
Grade: D
EW
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CTKB.
Margin of Safety
-544.4%
Fair Value
$12.31
Current Price
$82.67
$70.36 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 73.5% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Strong operational efficiency at 23.7%
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
ROE of -18.0% — below average capital efficiency
Negative free cash flow — burning cash
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 76.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : CTKB
The strongest argument for CTKB centers on EPS Growth, Debt/Equity, Altman Z-Score.
Bull Case : EW
The strongest argument for EW centers on Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 23.7%. Revenue growth of 13.3% demonstrates continued momentum.
Bear Case : CTKB
The primary concerns for CTKB are Market Cap, Piotroski F-Score, Return on Equity.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.7x leaves little room for execution misses.
Key Dynamics to Monitor
CTKB profiles as a turnaround stock while EW is a mature play — different risk/reward profiles.
CTKB carries more volatility with a beta of 1.31 — expect wider price swings.
EW is growing revenue faster at 13.3% — sustainability is the question.
EW generates stronger free cash flow (354M), providing more financial flexibility.
Bottom Line
EW scores higher overall (55/100 vs 41/100), backed by strong 17.7% margins and 13.3% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cytek Biosciences Inc
HEALTHCARE · MEDICAL DEVICES · USA
Cytek Biosciences Inc (CTKB) is a pioneering force in multi-parameter flow cytometry, providing state-of-the-art cell analysis solutions to the life sciences industry. The company's advanced technologies facilitate comprehensive cellular analyses that are crucial for research in immunology, cancer diagnostics, and drug development. With a commitment to innovation and excellence in customer service, Cytek has solidified its status as a key contributor in the biotechnology sector, addressing the growing need for precise cell analysis tools. Boasting a diverse product portfolio and a robust market position, the company continues to drive advancements in the rapidly evolving field of cell biology research.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?